Publikationen, an denen er mitarbeitet ISABEL CAMPOS VARELA (22)

2020

  1. Does retraction after misconduct have an impact on citations? A pre-post study

    BMJ Global Health, Vol. 5, Núm. 11

  2. Proceedings of the 25th annual congress of the international liver transplantation society

    Transplantation, Vol. 104, Núm. 8, pp. 1560-1565

  3. Recipient Age for Liver Transplantation: Should It Be Limited? A Propensity Score Matching Analysis of a Large European Series

    Transplantation Proceedings, Vol. 52, Núm. 5, pp. 1442-1449

  4. Retraction of publications: a study of biomedical journals retracting publications based on impact factor and journal category

    Gaceta Sanitaria, Vol. 34, Núm. 5, pp. 430-434

  5. Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States

    Transplantation, Vol. 104, Núm. 10, pp. 2078-2086

2019

  1. Misconduct as the main cause for retraction. A descriptive study of retracted publications and their authors

    Gaceta Sanitaria, Vol. 33, Núm. 4, pp. 356-360

  2. Some proposals on tracking scientific misconduct

    Gaceta Sanitaria

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  2. Food and drinks advertising directed at children on television during reinforced protection time slot in Spain, 2017

    Anales de Pediatria, Vol. 89, Núm. 3, pp. 186-187

  3. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series

    Clinical Transplantation, Vol. 32, Núm. 7

  4. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient

    Transplant Infectious Disease, Vol. 20, Núm. 1

2017

  1. Brief training in automated external defibrillation use for persons with down syndrome

    Resuscitation

  2. Sofosbuvir and daclatasvir in mono-and HIV-coinfected patients with recurrent hepatitis C After liver transplant

    Annals of Hepatology, Vol. 16, Núm. 1, pp. 86-93

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation

    Transplantation, Vol. 100, Núm. 3, pp. 593-599

  3. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus

    Clinical Transplantation, Vol. 30, Núm. 9, pp. 1140-1145

  4. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy

    Alimentary Pharmacology and Therapeutics, Vol. 43, Núm. 12, pp. 1319-1329

2015

  1. Advances in therapy for HIV/Hepatitis C virus-coinfected patients in the liver transplant setting

    Clinical Infectious Diseases, Vol. 60, Núm. 1, pp. 108-116

  2. Analysis of adult 20-year survivors after liver transplantation

    Hepatology International, Vol. 9, Núm. 3, pp. 461-470

  3. Doubtful role of IL28B polymorphism in occult Hepatitis B infection

    Intervirology, Vol. 58, Núm. 3, pp. 160-165